Biome Australia to Unveil Q4 FY26 Results and Global Expansion Strategy in August Investor Webinar

Biome Australia's Microbiome Health Platform and Activated Probiotics Portfolio

Founded in 2018, Biome Australia Limited specialises in developing, licensing, and marketing innovative, evidence-based live biotherapeutics and complementary medicines. The company collaborates with top global microbiome research organisations to develop its flagship Activated Probiotics range, utilising proprietary delivery technologies that enhance stability and efficacy. These products target health issues such as low mood, sleep disturbances, bone health, iron malabsorption, mild eczema, and irritable bowel syndrome.

Biome’s product development prioritises clinical validation, with the Activated Probiotics and Activated Therapeutics ranges supported by randomised double-blind placebo-controlled trials and other scientific research. Operating exclusively through practitioner-only distribution channels, Biome educates health professionals on the systemic health benefits of gut microbiota. This model focuses on delivering natural, evidence-based medicines to manage chronic and prevalent health conditions, setting the company apart in the complementary medicines industry.

Q4 FY26 Financial Results and Appendix 4C Cash Flow Statement

Biome Australia will lodge its Q4 FY26 quarterly results along with the Appendix 4C cash flow statement with the ASX on Wednesday, 29 July 2026 before market open. These disclosures will provide investors with detailed insights into the company’s operational and cash flow performance for the quarter ending 30 June 2026. The timing allows investors to review the financial data ahead of the investor webinar.

The quarterly results will be a core focus during the webinar, where company leaders will present and discuss key financial metrics, operational highlights, and cash management strategies detailed in the Appendix 4C. Investors can access the full financial statements via the ASX announcements platform, ensuring transparency and comprehensive visibility into Biome’s financial health.

International Market Expansion Across Canada, UK, Ireland, and New Zealand

The FY26 International Markets presentation, released on 27 July 2026, outlines Biome Australia’s active operations and distribution strategies in Canada, the United Kingdom, Ireland, and New Zealand. This includes channel partnerships, distribution agreements, and competitive positioning in each region. Ireland plays a strategic role as the EU gateway hub, enabling Biome to access and serve the wider European market.

The presentation also highlights onshore manufacturing capabilities and the upcoming launch of the Biome B2B2C direct wholesale and e-script portal in H1 FY27. This initiative marks a strategic shift towards direct-to-practitioner and direct-to-consumer channels, complementing the existing practitioner-only model. Expanding into these markets and establishing the EU gateway hub are key drivers of Biome’s international growth and revenue diversification beyond Australia.

B2B2C Portal Launch and Strategic Initiatives for H1 FY27

Biome Australia is developing a direct wholesale and e-script portal to enhance accessibility and streamline distribution in the first half of FY27. The B2B2C (business-to-business-to-consumer) platform will enable direct engagement with practitioners and consumers, reducing reliance on intermediaries and improving margins. This digital transformation reflects Biome’s commitment to modernising interactions with healthcare professionals and end-users across international markets.

The e-script functionality will allow practitioners to electronically prescribe and order products, increasing convenience and potentially boosting prescription volumes. This technology rollout represents a significant operational milestone, expected to improve efficiency and customer satisfaction. Launching in H1 FY27 positions Biome to capture greater market share and strengthen practitioner relationships through enhanced digital tools.

Leadership Insights During Investor Webinar

Founder and Managing Director Blair Vega Norfolk will lead the webinar alongside Chief Financial Officer Lauren Dwyer, combining strategic vision with financial expertise. Their joint presentation will offer investors a clear understanding of Biome’s long-term direction and near-term financial performance. The involvement of both executives underscores the importance of the webinar for shareholders seeking direct management insights.

The CFO will provide detailed explanations of financial results and cash management, complementing the broader market strategy discussion. The 45-minute session includes a live Q&A, giving investors the opportunity to engage directly with management on results, international expansion, and upcoming initiatives.

Investor Registration and Access to Interactive Investor Hub

Investors are encouraged to register in advance for the webinar via the Zoom link provided in Biome Australia’s company update. Registration ensures participants receive session reminders and access details ahead of the 10:00am AEST start on Monday, 3 August 2026.

Additionally, Biome maintains an interactive investor hub at investorhub.biomeaustralia.com, offering access to past presentations, subscription options for future updates, and corporate communications. This platform serves as a centralized resource for shareholders and prospective investors to stay informed about company developments and financial disclosures.

Live and Pre-Submitted Q&A Opportunities

The webinar will feature a live Q&A session, allowing investors to ask questions directly to management. For those preferring to submit questions in advance, Biome Australia provides an email submission option at [email protected]. This enables management to prepare thorough responses and address frequently raised topics during the session.

This dual approach to investor engagement—live interaction and pre-submission—maximizes opportunities for meaningful dialogue and ensures inclusivity for shareholders unable to attend live. Biome’s commitment to transparent communication fosters strong relationships with its investor base.

Clinical Research Foundation and Evidence-Based Product Differentiation

Biome Australia’s product portfolio is distinguished by rigorous clinical research and evidence-based development. Its Activated Probiotics and Activated Therapeutics ranges are supported by randomised double-blind placebo-controlled trials, a scientific standard rare in the complementary medicines sector. This clinical validation is a key competitive advantage, facilitating practitioner adoption domestically and internationally.

The company’s focus on evidence-based claims and clinical support underscores its dedication to credibility within the healthcare community. Collaborations with leading global microbiome research organisations and investment in clinical trials provide a strong foundation for product efficacy and practitioner education. This scientific approach positions Biome as a premium complementary medicines provider capable of commanding higher pricing and broader professional endorsement.

Microbiome Health Market Growth and Regulatory Landscape

The microbiome health sector has seen rapid growth and increasing acceptance, driven by expanding scientific knowledge of gut health’s impact on overall wellness. Consumer awareness linking microbiota to mood, sleep, immunity, and digestion has fueled demand for targeted probiotic and biotherapeutic products. This growth presents a significant opportunity for evidence-based companies like Biome Australia to capture market share among healthcare professionals and consumers seeking validated solutions.

Global regulatory frameworks for probiotics and complementary medicines are evolving, with heightened requirements for clinical substantiation and safety. Biome’s strong clinical research foundation positions it advantageously amid stricter regulations in markets such as Canada, the UK, and the European Union. Its international expansion, supported by clinical evidence and partnerships, leverages sector momentum while proactively managing regulatory risks through compliance and substantiation.